>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Tofacitinib citrate

Tofacitinib citrate 枸橼酸托法替尼; Tasocitinib citrate; CP-690550 citrate

Tofacitinib citrate是 JAK3/2/1 抑制剂，IC50 分别为1，20 和 112 nM。Tofacitinib citrate 具有抗菌，抗真菌和抗病毒活性。

货号：
TK0321
规格：

1mg

10mg

50mg

100mg
价格：
￥0.00

产品参数

CAS No.	540737-29-9
生物活性	Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.
分子式	C22H28N6O8
分子量	504.49
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	4°C, protect from light
溶解性数据	DMSO : 28.57 mg/mL (56.63 mM; Need ultrasonic) H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic)
体内研究	Animals that are treated with Tofacitinib show a significantly lower production of anti-drug antibodies (ADAs) compare with PEG-treated control mice (for five weeks after initial immunization, p<0.01, n=8). Moreover ADAs become detectable earliest on day 28. A difference of 1000- to 200-fold in titers to SS1P is apparent from days 21 through 35, respectively. Compare to SS1P, mice injected with keyhole limpet hemocyanin (KLH) generate a more rapid antibody response. Yet, the administration of Tofacitinib reduces anti-KLH titers compare to controls (p<0.05 on day 21, p<0.01 on day 28, respectively, n=5). Reductions in titers ranged from 5000- to 250-fold from days 21 through 28, respectively. Based on previous dose-response studies, a daily dose of Tofacitinib of 6.2 mg/kg is selected to provide 80% inhibition of hind paw volume and plasma exposure capable of suppressing the JAK1 and JAK3 signaling pathways for >4 hours.
体外研究	Tofacitinib (CP-690550) citrate binds potentially at JAK3 and JAK2 as 2.2 nM and 5 nM (Kd). The report includes additional binding for Tofacitinib at Camk1 (Kd of 5,000 nM), DCamkL3 (Kd of 4.5 nM), Mst2 (Kd of 4,300 nM), Pkn1 (Kd of 200 nM), Rps6ka2 (Kin.Dom.2-C-terminal) (Kd of 1,400 nM), Rps6ka6 (Kin.Dom.2-C-terminal) (Kd of 1,200 nM), Snark (Kd of 420 nM), Tnk1 (Kd of 640 nM) and Tyk2 (Kd of 620 nM). K562, KCL22, and THP-1 cells are exposed to different doses of STI571 or JAK inhibitors for 72 h to quantify the effects of tyrosine kinase inhibitor (TKI) activity. Cell growth inhibition is then evaluated using the MTT assay. The proliferation of K562 and KCL22 cells, but not THP-1 cells, is inhibited by IMA in a concentration-dependent manner. The IC50 value of IMA is 0.28 µM for K562 and 0.17 µM for KCL22. Although treatment with Tofacitinib (TOF) or INCB018424 alone does not suppress cell proliferation, both Tofacitinib and INCB018424 make the K562 and KCL22 more sensitive to IMA.
文献	•Ann Rheum Dis. 2021 Sep;80(9):1201-1208. •Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. •Cell Rep. 2020 Sep 15;32(11):108158. •Cell Mol Gastroenterol Hepatol. 2021 Oct 6;S2352-345X(21)00192-2. •BMC Med. 2021 Oct 15;19(1):247. •Cell Syst. 2018 Apr 25;6(4):424-443.e7. •J Med Chem. 2021 Feb 11. •Free Radic Biol Med. 2019 Aug 1;139:80-91. •Cell Prolif. 2021 Jan;54(1):e12933. •Food Chem Toxicol. 2020 Dec;146:111835. •Phytother Res. 2021 Feb;35(2):1033-1047. •Biochem Pharmacol. 2020 Aug;178:114103. •iScience. 2021 Sep 25;24(10):103173. •J Immunol. 2013 Oct 1;191(7):3568-77. •Inflamm Bowel Dis. 2020 Feb 11;26(3):407-422. •Sci Rep. 2021 Apr 1;11(1):7372. •J Pharmacol Exp Ther. 2019 Aug;370(2):137-147. •Mol Hum Reprod. 2021 Mar 24;27(4):gaab016. •Exp Cell Res. 2021 Feb 15;399(2):112482. •Exp Cell Res. 2020 Aug 1;393(1):112054. •J Biochem Mol Toxicol. 2021 Jul 31;e22851. •Pulm Pharmacol Ther. 2017 Apr;43:60-67. •PLoS One. 2018 Jan 10;13(1):e0189247. •Fundam Clin Pharmacol. 2021 Feb 1. •Arch Dermatol Res. 2020 Jul;312(5):337-352. •Int J Rheum Dis. 2020 Aug;23(8):1066-1075. •Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11. •Biomed Chromatogr. 2021 Feb 1;e5081. •Chemrxiv. Aug 11, 2021. •bioRxiv. 2020 Dec 9;2020.12.09.416586. •Patent. US20180263995A1.
纯度及产品资料	98%

推荐产品